24
Oct
2024
Intellia In Vivo Disappoints, Seaport Aims at Anxiety, & Wave Shows RNA Editing Promise
Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $199 per year, you reward quality independent biotech reporting, and encourage more. Subscribe Now Sign in to your account.
24
Oct
2024
Yes We Can: My Response To Skeptical Readers
Two weeks ago, I wrote about how difficult it is for R&D leaders to “pick winners,” despite the enormous incentives to do so. I explained how we tend to underestimate the role of chance, and overestimate our ability to “domesticate uncertainty,” as Nassim Taleb and I wrote in the Financial Times in 2008. Mostly, efforts to systematically improve success rates... Read More